Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhaoke Ophthalmology Limited
兆科眼科有限公司
(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

VOLUNTARY ANNOUNCEMENT – ENTERING INTO STRATEGIC PARTNERSHIP WITH TSH BIOPHARM TO COMMERCIALIZE BRIMOCHOL™ PF IN TAIWAN REGION

This announcement is made by the board of directors (the "**Board**") of Zhaoke Ophthalmology Limited (the "**Company**") on a voluntary basis.

The Board of the Company is pleased to announce that the Company has entered into a strategic partnership with Taiwan-based TSH Biopharm Corporation Limited to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan Region. TSH Biopharm specializes in chronic diseases and precision medicine, providing safe and accessible care solutions.

Under the terms of the agreement, Zhaoke grants TSH, as its exclusive distributor, the right to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan Region.

In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke's partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA accepted its New Drug Application ("**NDA**"). The FDA has set a Prescription Drug User Fee Act ("**PDUFA**") date of 28 January 2026 for BRIMOCHOL™ PF.

ABOUT BRIMOCHOL™ PF AND BRIO-II PHASE 3 STUDY

BRIMOCHOL™ PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.

ABOUT PRESBYOPIA

Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s[1] and becomes almost universal by age 50[2]. Presbyopia impacts billions of people globally[3] with approximately 600 million adults affected in China, South Korea and Southeast Asia[4]. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData[5]. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.

ABOUT TSH BIOPHARM CORPORATION LIMITED

Founded in 2010, TSH Biopharm Corporation Limited (TW-8432) is a Taiwan-based pharmaceutical company committed to patient-centric care and long-term disease management. The company specializes in chronic therapeutic areas – cardiovascular, gastrointestinal, central nervous system, and ophthalmology – delivering safe, effective, and accessible solutions that address unmet needs in daily disease control and improve quality of life.

To meet evolving healthcare needs, TSH Biopharm has expanded beyond chronic-disease therapeutics into prevention and precision medicine, establishing an integrated framework that spans prevention, diagnosis, and treatment. Key initiatives – including probiotics, vaccines, and next-generation sequencing (NGS) testing – underscore the company's commitment to comprehensive, high-value healthcare.

Driven by its vision to enhance patient quality of life and serve as a preferred strategic partner for global biomedical innovation in Asia, TSH Biopharm continues to strengthen its chronic-care leadership, accelerate technology-driven innovation, and expand across emerging Asian markets. The company upholds strong corporate responsibility and governance standards, aiming to create long-term, sustainable impact on public health.

ABOUT TENPOINT THERAPEUTICS

Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts

1 World report on vision. (2019). Retrieved 29 April, 2022, from https://www.who.int/docs/default-source/documents/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2

2 Polat, U., Schor, C., Tong, JL. et al. Training the brain to overcome the effect of aging on the human eye. Sci Rep 2, 278 (2012). https://doi.org/10.1038/srep00278

3 Market Scope, Global Presbyopia-Correcting Surgery Market Report. April 2012.

4 Tenpoint Therapeutics data on file

5 GlobalData's Epidemiology Market Size Search extracted on 18 December 2024.

approximately two billion people globally. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the New Drug Application (NDA) and has received a Prescription Drug User Fee Act (PDUFA) date from the U.S. Food and Drug Administration (FDA) of January 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop, or commercialize BRIMOCHOL™ PF successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, December 8, 2025

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.